Drug Database
OX

oxcarbazepine (SPN604 / SPN 804 / oxcarbazepine ER)

✓ Approved

Aequus Pharmaceuticals, Inc. · SCN1A · 小分子

什么是 oxcarbazepine?

oxcarbazepine 是一种小分子,由Aequus Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名SPN604, SPN 804, oxcarbazepine ER
公司Aequus Pharmaceuticals, Inc.
药物类别小分子
分子靶点SCN1A, SCN2A, SCN3A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

oxcarbazepine 作用于 3 个分子靶点:

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

oxcarbazepine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersPartial seizures✓ Approved
Psychiatric disordersBipolar disorderPhase III

相关研究文献

PubMedEpilepsia open2026-11-15

Real-world antiseizure medication prescribing and treatment pathways in a pediatric health care system.

Abend Jack E JE, Gonzalez Alex K AK, Kaufman Michael C MC, Fitzgerald Mark P MP

To characterize antiseizure medication (ASM) selection, subsequent ASM prescribing, and treatment pathways among patients with epilepsy receiving care within a pediatric health care system. We conducted a retrospective electronic health record study over 17 years. Each unique ASM was counted once per patient, and ASMs were ordered by the date of their first observed prescription. For each observed ASM, we determined whether a subsequent unique ASM was prescribed during available follow-up. Prescription of a third unique ASM was used as a proxy for potential drug-resistant epilepsy. Among 20 009 patients, 27 ASMs and 3507 treatment pathways were identified. The most common first-observed ASMs were levetiracetam (35.1%), oxcarbazepine (17.2%), and valproic acid (12.3%). From 2010 to 2026, the proportion of first-observed prescriptions for levetiracetam increased from 23.1% to 41.5%. The proportion of all distinct ASMs first recorded for individual patients that were newer-generation ASMs increased from 0% in 2010 to 9.1% in 2026. The proportion of patients without a subsequent ASM ranged from 16.2% to 69.6% across commonly prescribed first-observed ASMs. Overall, 55.6% of patients had one unique ASM recorded, 22.4% had two, and 22.0% had at least three, thereby meeting the study's prescription-based proxy for potential drug-resistant epilepsy. Beyond the most common single- and two-ASM pathways, each remaining pathway accounted for less than 1% of the cohort. Prescribing remained concentrated among established ASMs, although their relative use changed substantially. The proportion of patients without a subsequent ASM varied widely across medications, and treatment pathways beyond first-observed therapy were highly heterogeneous. These findings characterize real-world treatment patterns and identify a need for comparative effectiveness studies of ASM sequencing. We examined antiseizure medication prescribing over 17 years among more than 20 000 patients with epilepsy receiving care in a pediatric health care system. More than half had only one medication recorded, whereas 22% had at least three medications; however, the available records could not determine whether these medications failed to control seizures. Levetiracetam became more commonly prescribed, newer medications remained a small proportion of overall use, and medication sequences varied widely after the first observed treatment. These findings highlight the need for better evidence to guide medication selection after initial treatment.

PMID 43033003
阅读全文 →
PubMedCureus2026-10-28

Isolated Oral and Esophageal Mucosal Injury as a Rare Oxcarbazepine Adverse Drug Reaction: A Case Report.

De Jesus-Gonzalez Joselyn J, Federico Quinten P QP, Malafronte Patrick P, Champeaux Anne A et al.

Drug-induced mucosal injury may result from direct contact toxicity or immune-mediated adverse drug reactions. Although oxcarbazepine is a recognized etiology of severe hypersensitivity reactions, isolated oroesophageal mucosal injury without cutaneous or systemic involvement has not been previously described. We report a 68-year-old woman who developed severe diffuse esophagitis with concomitant oral mucosal ulceration approximately two weeks after oxcarbazepine initiation, with symptom onset within 24 hours of dose escalation from 150 to 300 mg twice daily. Histologic evaluation demonstrated predominantly lymphocytic esophageal inflammation with no evidence of infectious, eosinophilic, or immunobullous disease. The patient had no rash, peripheral eosinophilia, or systemic organ involvement. A Naranjo score of 7 supported a probable adverse drug reaction. Treatment consisted of discontinuation of oxcarbazepine alone, without the need for immunosuppressive or additional pharmacologic therapy. At five-month follow-up, the patient achieved endoscopic and histologic resolution. This case expands upon the recognized spectrum of oxcarbazepine-associated adverse drug reactions and emphasizes the importance of medication review in patients presenting with diffuse esophagitis and oral mucositis.

PMID 42948823
阅读全文 →
PubMedActa epileptologica2026-10-28

Pharmacokinetic changes and seizure outcomes in pregnant women taking second-generation antiseizure medications.

Hao Nanya N, Yi Xiaoli X, Zhao Renjie R, Zhang Xuechen X et al.

Effective seizure management in pregnant women with epilepsy poses significant clinical challenges. This study aimed to investigate the pharmacokinetic changes of second-generation antiseizure medications (ASMs) and their association with the deterioration of seizure control in Han Chinese women with epilepsy. Patient clinical data including oral daily doses and seizure frequency were acquired from routine clinical practice. Blood concentrations of ASMs determined by therapeutic drug monitoring (TDM) were used to calculate apparent oral clearance (CL) at preconception and each trimester during pregnancy. The ratio of ASM concentration in each trimester to the preconception baseline concentration (RTC) was compared between patients experiencing seizure deterioration and those maintaining stability. Moreover, receiver operating characteristic (ROC) curve analysis was used to identify the threshold RTC value predicting increased seizure frequency. A total of 52 pregnant patients with epilepsy were initially enrolled in this study. The apparent oral clearance of levetiracetam (LEV) and lamotrigine (LTG) showed a significant increase across all trimesters compared to the nonpregnant baseline. Peak clearance occurred in the third trimester for LTG with a 2.0-fold relative clearance (P < 0.05). Similarly, LEV displayed maximum apparent oral clearance increase during the third trimester, reaching 1.6 folds of baseline value (P < 0.05). As a result, serum concentrations of LEV and LTG significantly decreased during pregnancy compared to non-pregnant baseline levels (P < 0.05). However, the apparent oral clearance and the blood level of oxcarbazepine (OXC) remained stable throughout gestation compared to the preconception baseline. Moreover, the RTC values significantly differed between participants with and without seizure deterioration for all three ASMs, indicating that lower RTCs were associated with seizure worsening. Our study revealed significant pharmacokinetic fluctuations of LEV and LTG in Chinese pregnant women. This highlights the necessity of early therapeutic drug monitoring for newer ASMs and dose adjustments to maintain blood concentrations near the non-pregnant baseline level in pregnant women with epilepsy.

PMID 42947279
阅读全文 →
PubMedEpileptic disorders : international epilepsy journal with videotape2026-10-28

Comparative efficacy of first-line antiseizure monotherapy in pediatric focal epilepsy: An umbrella review of systematic reviews and meta-analyses.

Karaahmet Aysu Yildiz AY, Bilgiç Fatma Şule FŞ, Yüksel Adnan A

First-line antiseizure medication (ASM) monotherapy remains the recommended initial treatment for pediatric focal epilepsy. Although several ASMs are available, uncertainty persists regarding their comparative efficacy, safety, and tolerability, particularly in children. This umbrella review aimed to synthesize and map the available evidence from systematic reviews and meta-analyses evaluating first-line ASM monotherapies for focal epilepsy, with a focus on informing pediatric treatment decisions. This umbrella review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. Systematic reviews and meta-analyses evaluating first-line ASM monotherapy for focal epilepsy were identified through comprehensive database searches. Data on study characteristics, patient populations, ASM comparisons, epilepsy subtypes, follow-up duration, efficacy, safety, and tolerability outcomes were extracted and synthesized descriptively. Evidence mapping was performed to summarize the findings, and potential overlap of primary studies across the included reviews was considered. Where available, outcome-specific certainty-of-evidence ratings reported by the source reviews using GRADE or CINeMA were also extracted and summarized. Sixteen systematic reviews and meta-analyses were included, comprising randomized controlled trials and individual participant data analyses from pediatric and mixed-age populations. Frequently evaluated ASMs included carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, valproate, phenytoin, and several newer-generation agents. Across the included reviews, no single first-line ASM showed consistent superiority for seizure control outcomes. Selected comparisons suggested tolerability advantages for lamotrigine, levetiracetam, and some newer-generation ASMs; however, these findings were not uniform across outcomes or reviews. Several comparative estimates were imprecise, with confidence intervals encompassing potentially clinically meaningful effects, and substantial heterogeneity was present across epilepsy subtype definitions, patient populations, follow-up durations, and outcome reporting. The frequent inclusion of mixed-age populations further limited the strength and direct applicability of pediatric-specific conclusions. Current umbrella-level evidence does not establish clear superiority of one first-line ASM over another for seizure control in pediatric focal epilepsy. Importantly, the absence of statistically significant differences should not be interpreted as evidence of therapeutic equivalence, because several estimates remain imprecise and clinically meaningful differences cannot be excluded. Interpretation is further limited by the scarcity of pediatric-specific comparative data, the frequent inclusion of mixed-age populations, and methodological and outcome heterogeneity across reviews. Safety and tolerability should therefore be considered alongside efficacy when individualizing treatment selection. Well-designed pediatric-specific comparative studies using standardized outcome measures are needed to strengthen evidence-based treatment recommendations.

PMID 42949619
阅读全文 →
PubMedPharmaceutics2026-10-27

Physiologically Constrained Deep Learning in Physiologically Based Pharmacokinetic Modeling: Virtual Patient Generation, Machine-Learned Scaling Laws, and Pediatric Precision Dosing.

Zhang Lei L, Xu Yichao Y

Physiologically based pharmacokinetic (PBPK) modeling is now central to pediatric dose selection, because clinical sampling in children is ethically constrained and simple weight-based scaling is unreliable while organ function and enzyme activity are still maturing. Three bottlenecks limit classical PBPK in this setting, namely building physiologically coherent virtual patient populations, extrapolating drug disposition across species and age, and estimating many mechanism-linked parameters from sparse data. Over the past five years, deep learning has begun to address each. Generative models constrained by physiological knowledge create virtual patients that preserve realistic correlations and whole-body coherence. Graph networks and neural ordinary differential equations learn continuous scaling and maturation relationships instead of relying on fixed exponents. Physics-informed networks and surrogate emulators estimate mechanistic parameters and quantify uncertainty in data-poor pediatric settings. This review surveys these developments, organizes them by the PBPK workflow they serve, and links them to precision dosing of three antiepileptic drugs, lacosamide, lamotrigine, and oxcarbazepine. Unlike earlier surveys focused on concentration prediction and therapeutic drug monitoring, we keep the mechanistic model in the foreground, treating the virtual patient as the unit of simulation. We also discuss open problems, including validation standards for generated populations, the regulatory qualification of learning-enhanced PBPK, uncertainty reporting, and the prospect of foundation models of pharmacokinetics. Throughout, we distinguish methodological maturity from demonstrated clinical benefit.

PMID 42942788
阅读全文 →
PubMedBMC pregnancy and childbirth2026-10-27

Prenatal antiseizure medication exposure and offspring structural and neurodevelopmental outcomes: an umbrella review of systematic reviews and meta-analyses.

Li Yulong Y, Fu Yutong Y, Duan Yifei Y, Shi Fanfan F et al.

Review-level evidence on prenatal antiseizure medication (ASM) exposure is difficult to interpret because outcome domains are often synthesized separately, primary studies overlap, and comparator frameworks and certainty vary. We aimed to calibrate evidence across structural and neurodevelopmental outcomes. We conducted an anchor-based umbrella review of systematic reviews and meta-analyses (PROSPERO: CRD420251142541), searching four databases through December 31, 2025. One prespecified anchor review represented each drug-outcome-comparator question; overlapping reviews were not combined into second-order pooled estimates. AMSTAR 2, corrected covered area, GRADE, and directional umbrella-credibility classes were applied, with NS assigned when the 95% confidence interval included the null. Fourteen reviews were included: nine structural and five neurodevelopmental. All had Low or Critically Low AMSTAR 2 confidence, and ASD/ADHD review overlap was very high (CCA, 28.1%). Valproate showed the most consistent retained pattern, including Class I credibility for combined major congenital anomalies and the most credible retained neurodevelopmental signal for autism spectrum disorder (adjusted hazard ratio, 3.10; 95% CI, 2.24-4.28; Low certainty; Class II). Topiramate showed an oral-cleft signal with Low certainty and Class III credibility. The lamotrigine estimate for major congenital anomalies was NS, whereas the orofacial-cleft estimate excluded the null but had Very Low certainty (OR, 1.42; 95% CI, 1.05-1.92; Class IV). Other retained neurodevelopmental anchors had Very Low certainty and were Class IV or NS; no independent pairwise neurodevelopmental anchor was available for carbamazepine, oxcarbazepine, topiramate, or levetiracetam. Review-level evidence was most consistent for valproate and aligned with its established structural and neurodevelopmental risks. NS or Very Low-certainty findings for non-valproate ASMs should not be interpreted as evidence of no risk. Comparative safety requires individualized risk-benefit assessment rather than binary safety classifications.

PMID 42934576
阅读全文 →

注册免费账户还可查看另外 2628 篇文献

免费注册查看全部文献 →

了解更多oxcarbazepine